CDT Equity Inc. (NASDAQ:CDT) Sees Significant Growth in Short Interest

CDT Equity Inc. (NASDAQ:CDT) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 210,800 shares, an increase of 95.9% from the August 31st total of 107,600 shares. Based on an average daily trading volume, of 4,070,000 shares, the short-interest ratio is currently 0.1 days. Based on an average daily trading volume, of 4,070,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a report on Saturday, September 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

CDT Equity Stock Up 22.9%

CDT Equity stock opened at $0.83 on Tuesday. The firm has a market cap of $2.54 million, a P/E ratio of 0.00 and a beta of 1.81. The business has a fifty day moving average of $1.23 and a two-hundred day moving average of $4.19. CDT Equity has a twelve month low of $0.57 and a twelve month high of $274.80.

CDT Equity (NASDAQ:CDT) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($5.46) earnings per share for the quarter.

Hedge Funds Weigh In On CDT Equity

An institutional investor recently raised its position in CDT Equity stock. Citadel Advisors LLC lifted its holdings in CDT Equity Inc. (NASDAQ:CDT) by 177.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 526,268 shares of the company’s stock after purchasing an additional 336,278 shares during the quarter. Citadel Advisors LLC owned about 51.09% of CDT Equity worth $36,000 as of its most recent SEC filing. 3.29% of the stock is currently owned by hedge funds and other institutional investors.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.